| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Jan, 2026 |
| Sales | 1,270 | 1,080 | 490 | 0 | 0 |
| Sales Growth | +17.59% | +120.41% | unch | unch | unch |
| Net Income | -58,800 | -19,770 | -76,100 | -32,560 | 0 |
| Net Income Growth | -197.42% | +74.02% | -133.72% | unch | unch |
Baudax Bio Inc (BXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Baudax Bio Inc. is based in Malvern, Pennsylvania.